Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2

David Roger Adams, Salha Tawati, Giacomo Berretta, Paula Lopez Rivas, Jessica Baiget, Zhong Jiang, Aisha Alsfouk, Simon P. Mackay, Nigel Pyne, Susan Pyne

Research output: Contribution to journalArticle

Abstract

Sphingosine kinase enzymes (SK1 and SK2) catalyse the conversion of sphingosine into sphingosine 1-phosphate and play a key role in lipid signaling and cellular responses. Mapping of isoform amino acid sequence differences for SK2 onto the recently available crystal structures of SK1 suggests that subtle structural differences exist in the foot of the lipid-binding ‘J-channel’ in SK2, the structure of which has yet to be defined by structural biology techniques. We have probed these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-543. Here we show how it is possible, even with relatively conservative changes in compound structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective inhibition, through equipotent SK1/SK2 inhibition, to reversed 100-fold SK2 selectivity, with retention of nanomolar potency.
Original languageEnglish
Pages (from-to)3658-3676
Number of pages19
JournalJournal of Medicinal Chemistry
Volume62
Issue number7
Early online date19 Mar 2019
DOIs
Publication statusPublished - 11 Apr 2019

Fingerprint

Protein Isoforms
Ligands
Lipids
Sphingosine
Foot
Amino Acid Sequence
sphingosine kinase
PF-543
sphingosine 1-phosphate
sulfurylase kinase

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Adams, David Roger ; Tawati, Salha ; Berretta, Giacomo ; Lopez Rivas, Paula ; Baiget, Jessica ; Jiang, Zhong ; Alsfouk, Aisha ; Mackay, Simon P. ; Pyne, Nigel ; Pyne, Susan. / Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2. In: Journal of Medicinal Chemistry. 2019 ; Vol. 62, No. 7. pp. 3658-3676.
@article{bbbd4f7716cc4243a1e7550a9d85634d,
title = "Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2",
abstract = "Sphingosine kinase enzymes (SK1 and SK2) catalyse the conversion of sphingosine into sphingosine 1-phosphate and play a key role in lipid signaling and cellular responses. Mapping of isoform amino acid sequence differences for SK2 onto the recently available crystal structures of SK1 suggests that subtle structural differences exist in the foot of the lipid-binding ‘J-channel’ in SK2, the structure of which has yet to be defined by structural biology techniques. We have probed these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-543. Here we show how it is possible, even with relatively conservative changes in compound structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective inhibition, through equipotent SK1/SK2 inhibition, to reversed 100-fold SK2 selectivity, with retention of nanomolar potency.",
author = "Adams, {David Roger} and Salha Tawati and Giacomo Berretta and {Lopez Rivas}, Paula and Jessica Baiget and Zhong Jiang and Aisha Alsfouk and Mackay, {Simon P.} and Nigel Pyne and Susan Pyne",
note = "Tuesday 19-Mar-2019: this paper has just been accepted and should be published online within a day or two as a'just accepted manuscript' at: https://pubs.acs.org/toc/jmcmar/0/ja Wednesday 20-Mar-2019: AAM added to PURE with the journal's 'just accepted manuscript' cover page inc. doi and online publication date. Monday 15-Apr-2019: updated volume/issue/pagination information for published article.",
year = "2019",
month = "4",
day = "11",
doi = "10.1021/acs.jmedchem.9b00162",
language = "English",
volume = "62",
pages = "3658--3676",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

Adams, DR, Tawati, S, Berretta, G, Lopez Rivas, P, Baiget, J, Jiang, Z, Alsfouk, A, Mackay, SP, Pyne, N & Pyne, S 2019, 'Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2', Journal of Medicinal Chemistry, vol. 62, no. 7, pp. 3658-3676. https://doi.org/10.1021/acs.jmedchem.9b00162

Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2. / Adams, David Roger; Tawati, Salha; Berretta, Giacomo; Lopez Rivas, Paula; Baiget, Jessica; Jiang, Zhong; Alsfouk, Aisha; Mackay, Simon P.; Pyne, Nigel; Pyne, Susan.

In: Journal of Medicinal Chemistry, Vol. 62, No. 7, 11.04.2019, p. 3658-3676.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2

AU - Adams, David Roger

AU - Tawati, Salha

AU - Berretta, Giacomo

AU - Lopez Rivas, Paula

AU - Baiget, Jessica

AU - Jiang, Zhong

AU - Alsfouk, Aisha

AU - Mackay, Simon P.

AU - Pyne, Nigel

AU - Pyne, Susan

N1 - Tuesday 19-Mar-2019: this paper has just been accepted and should be published online within a day or two as a'just accepted manuscript' at: https://pubs.acs.org/toc/jmcmar/0/ja Wednesday 20-Mar-2019: AAM added to PURE with the journal's 'just accepted manuscript' cover page inc. doi and online publication date. Monday 15-Apr-2019: updated volume/issue/pagination information for published article.

PY - 2019/4/11

Y1 - 2019/4/11

N2 - Sphingosine kinase enzymes (SK1 and SK2) catalyse the conversion of sphingosine into sphingosine 1-phosphate and play a key role in lipid signaling and cellular responses. Mapping of isoform amino acid sequence differences for SK2 onto the recently available crystal structures of SK1 suggests that subtle structural differences exist in the foot of the lipid-binding ‘J-channel’ in SK2, the structure of which has yet to be defined by structural biology techniques. We have probed these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-543. Here we show how it is possible, even with relatively conservative changes in compound structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective inhibition, through equipotent SK1/SK2 inhibition, to reversed 100-fold SK2 selectivity, with retention of nanomolar potency.

AB - Sphingosine kinase enzymes (SK1 and SK2) catalyse the conversion of sphingosine into sphingosine 1-phosphate and play a key role in lipid signaling and cellular responses. Mapping of isoform amino acid sequence differences for SK2 onto the recently available crystal structures of SK1 suggests that subtle structural differences exist in the foot of the lipid-binding ‘J-channel’ in SK2, the structure of which has yet to be defined by structural biology techniques. We have probed these isoform differences with a ligand series derived from the potent SK1-selective inhibitor, PF-543. Here we show how it is possible, even with relatively conservative changes in compound structure, to systematically tune the activity profile of a ligand from ca. 100-fold SK1-selective inhibition, through equipotent SK1/SK2 inhibition, to reversed 100-fold SK2 selectivity, with retention of nanomolar potency.

UR - http://www.scopus.com/inward/record.url?scp=85064229836&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.9b00162

DO - 10.1021/acs.jmedchem.9b00162

M3 - Article

VL - 62

SP - 3658

EP - 3676

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -